Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone857-246-8998
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.10 million
Profitability
Miscellaneous
Employees107
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings results on Friday, May, 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company had revenue of $8.55 million for the quarter, compared to analysts' expectations of $7.85 million. Pieris Pharmaceuticals had a negative net margin of 84.75% and a negative return on equity of 64.64%. View Pieris Pharmaceuticals' Earnings History.
When is Pieris Pharmaceuticals' next earnings date?
What price target have analysts set for PIRS?
3 brokers have issued twelve-month price targets for Pieris Pharmaceuticals' shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.
What is the consensus analysts' recommendation for Pieris Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.
What are Wall Street analysts saying about Pieris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. " (7/11/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and are increasing our price target to $7 from $5. The two drivers for our valuation change include: (1) adjustment to base year; and (2) increasing our projected chance of success for to 25%. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/10/2019)
Has Pieris Pharmaceuticals been receiving favorable news coverage?
Media coverage about PIRS stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Pieris Pharmaceuticals.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include STARPHARMA HOLD/S (SPHRY), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM), Geovax Labs (GOVX), Protalex (PRTX) and ALGAE TEC LTD/S (ALGXY).
What other stocks do shareholders of Pieris Pharmaceuticals own?
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
- Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
- Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
- Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
- Maria Kelman, Director of Investor Relations
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $4.52.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $222.16 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.
What is Pieris Pharmaceuticals' official website?
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)
| Community Ranking: | | 2.7 out of 5 ( ) |
| Outperform Votes: | | 221 (Thanks for Voting!) |
| Underperform Votes: | | 193 (Thanks for Voting!) |
| Total Votes: | | 414 |
